![]() ![]() The following ISI is based on the Highlights section of the US Prescribing Information for Trelegy Ellipta. Important Safety Information (ISI) for Trelegy Ellipta About Trelegy Elliptaįull US Prescribing Information, including BOXED WARNING and Medication Guide is available at: us.gsk.com. ![]() Understanding this, and providing support to help meet these needs is the foundation of GSK’s work. Įvery person with COPD is different, with different needs, different challenges and different goals. Most people who have COPD are at least 40 years old when symptoms begin. Cigarette smoke, breathing in second hand smoke, air pollution, chemical fumes or dust from the environment or workplace can all contribute to COPD. Long-term exposure to lung irritants that damage the lungs and the airways are usually the cause of COPD. įor people living with COPD the inability to breathe normally and worsening of their symptoms can consume their daily life and make simple activities, like walking upstairs, an everyday struggle. It is thought to affect 384 million people worldwide. FF/UMEC/VI is not licensed as a single inhaler triple therapy anywhere outside of the US.ĬOPD is a disease of the lungs that includes chronic bronchitis, emphysema or both and limits airflow to the lungs, interfering with normal breathing. The proposed trade name Trelegy Ellipta remains subject to regulatory approval in Europe. Positive Opinion is one of the final steps before marketing authorisation is granted by the European Commission. On 15 September 2017, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorisation for FF/UMEC/VI as maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. Regulatory applications have been submitted and are undergoing assessment in a number of other countries, including the European Union, Australia and Canada. Trelegy Ellipta is the latest development in our collaboration with GSK and is testament to our ongoing efforts to advance respiratory medicine.”įollowing this approval by the FDA, Trelegy Ellipta will be available in the US shortly. Mike Aguiar, CEO of Innoviva, Inc., added, “This approval represents a significant therapeutic convenience for those appropriate patients already on Breo Ellipta, that require additional bronchodilation or for those patients already on a combination of Breo Ellipta and Incruse Ellipta. The approval of Trelegy Ellipta, and the addition of a once-daily single inhaler triple therapy to our portfolio of respiratory medicines, is an important milestone for GSK that builds on our long heritage in this area.” The FDA-approved strength is FF/UMEC/VI 100/62.5/25 mcg.Įric Dube, SVP & Head, GSK Global Respiratory Franchise, said, “COPD is a progressive disease that can worsen over time, and represents a significant burden to patients and healthcare systems. It is the first once-daily product approved in the US that combines three active molecules in a single inhaler for the maintenance treatment of appropriate patients with COPD. Trelegy Ellipta is a combination of an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA), delivered once-daily in GSK’s Ellipta dry powder inhaler. Trelegy Ellipta is not indicated for relief of acute bronchospasm or the treatment of asthma. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired or for patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol. GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |